期刊
CELLS
卷 10, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/cells10092263
关键词
DYRK1A; beta-cell; kinase; inhibitor; diabetes; hiPSC; organoid; drug development
类别
资金
- National Science Centre Poland within the Sonata Bis 9 project [2019/34/E/NZ1/00467]
- NAWA Polish National Agency for Academic Exchange grant [PPN/PPO/2018/1/00046]
This study demonstrates the efficacy of a set of small molecule inhibitors of DYRK1A kinase in promoting beta-cell proliferation, enhancing long-term insulin secretion, and balancing glucagon level in human islets. The compounds show significantly more pronounced effects compared to harmine and hold considerable promise for regenerative medicine in the treatment of T1DM and T2DM.
The rising prevalence of diabetes is threatening global health. It is known not only for the occurrence of severe complications but also for the SARS-Cov-2 pandemic, which shows that it exacerbates susceptibility to infections. Current therapies focus on artificially maintaining insulin homeostasis, and a durable cure has not yet been achieved. We demonstrate that our set of small molecule inhibitors of DYRK1A kinase potently promotes beta-cell proliferation, enhances long-term insulin secretion, and balances glucagon level in the organoid model of the human islets. Comparable activity is seen in INS-1E and MIN6 cells, in isolated mice islets, and human iPSC-derived beta-cells. Our compounds exert a significantly more pronounced effect compared to harmine, the best-documented molecule enhancing beta-cell proliferation. Using a body-like environment of the organoid, we provide a proof-of-concept that small-molecule-induced human beta-cell proliferation via DYRK1A inhibition is achievable, which lends a considerable promise for regenerative medicine in T1DM and T2DM treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据